Skip to content 
Prediabetes Clinical Trials: The Window You Do Not Want to Miss
110+ million Americans have prediabetes. The majority do not know it. And the window to reverse it is closing — but research is creating new tools to keep it open.
Prediabetes is one of the most consequential diagnoses in primary care — and one of the most frequently underestimated by patients who receive it, despite a growing number of prediabetes clinical research working to change that. A fasting blood sugar between 100 and 125 mg/dL, or an HbA1c between 5.7% and 6.4%, puts you in the prediabetes range. Your doctor may mention it briefly, recommend you watch your diet, and move on.
But prediabetes is not a near-miss or a mild warning. It is an active metabolic state with serious implications — and for many patients, it is already doing damage to blood vessels and organs before the blood sugar ever formally crosses into the diabetic range.
What Is Actually Happening in Your Body With Prediabetes
Chronically elevated insulin levels drive fat storage, particularly visceral fat. They promote inflammation. They accelerate arterial disease. And over time, the pancreas itself begins to wear out from the sustained overproduction — at which point blood sugar rises into the diabetic range, often with remarkable speed.
70% of people with prediabetes will eventually develop Type 2 diabetes — but lifestyle intervention and early treatment can reduce that risk by more than 58%.
Can Prediabetes Be Reversed?
Yes — particularly in its earlier stages. The landmark Diabetes Prevention Program (DPP) clinical trial demonstrated that intensive lifestyle intervention (modest weight loss and regular physical activity) reduced progression from prediabetes to Type 2 diabetes by 58% in adults over age 25, and by 71% in adults over age 60.
Metformin, a medication long used for Type 2 diabetes, also showed a 31% reduction in progression in the same trial. Newer drug classes are now being studied specifically in the prediabetic population — with preliminary results suggesting even more significant effects.
Prediabetes Clinical Trials: What Research Is Studying
- GLP-1 receptor agonists (i.e. semaglutide) in people with prediabetes and obesity — to determine whether the dramatic metabolic improvements seen in diabetic patients can prevent diabetes from ever developing
- Novel insulin sensitizers that address the root cause of insulin resistance rather than managing downstream blood sugar effects
- Combination lifestyle-pharmacology programs that pair medication with structured behavioral coaching
- Biomarkers that predict which prediabetic patients are most at risk for progression — enabling earlier, more targeted intervention
The Most Important Thing Your Doctor Has Not Said Yet
If you have been told you have prediabetes and sent home with a pamphlet about diet, you have received incomplete medical care. Prediabetes deserves the same clinical attention as any other cardiovascular risk factor — because the insulin resistance driving it is already damaging your blood vessels, your liver, and your metabolic future.
Ask your doctor to calculate your cardiovascular risk in the context of your prediabetes. Ask about clinical trials. Ask whether a medication trial might be appropriate given your other risk factors. You are not in a waiting room for diabetes — you are in a window that is still open.
